Breaking News

BioVaxys Acquires Critical Lipid Supply for DPX Platform

Prepares for preclinical and clinical program ramp-up.

Author Image

By: Charlie Sternberg

Associate Editor

In anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, BioVaxys Technology Corp. has acquired a 48-kilogram supply of GMP-grade lipid to enable production of the Company’s DPX antigen packaging delivery platform.   These unused lipids from the former IMV Inc., had been previously produced in advance of anticipated IMV clinical studies and commercial ramp-up. In February 2024, BioVaxys acquired 100% of the intellectual property a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters